Rare primary hyperaldosteronism

Rare primary hyperaldosteronism (also known as rare primary aldosteronism) encompasses a group of uncommon genetic conditions in which the adrenal glands produce excessive amounts of the hormone aldosterone. This overproduction leads to sodium retention and potassium excretion by the kidneys, resulting in hypertension (high blood pressure) and hypokalemia (low potassium levels). The condition primarily affects the cardiovascular system, kidneys, and adrenal glands. Key clinical features include resistant hypertension, muscle weakness, fatigue, headaches, and in some cases cardiac arrhythmias related to electrolyte imbalances. Some patients may also experience polyuria (excessive urination) and polydipsia (excessive thirst). This Orphanet grouping includes several rare familial and genetic forms of primary hyperaldosteronism, such as familial hyperaldosteronism types I (glucocorticoid-remediable aldosteronism, caused by a CYP11B1/CYP11B2 chimeric gene), type II (linked to CLCN2 mutations), type III (caused by KCNJ5 mutations), and type IV (caused by CACNA1H mutations), as well as aldosterone-producing adenomas associated with somatic mutations. These forms are distinguished from the more common sporadic primary aldosteronism by their genetic basis and, in some cases, earlier age of onset. Treatment depends on the specific subtype. Familial hyperaldosteronism type I can be effectively managed with low-dose glucocorticoids (such as dexamethasone), which suppress ACTH-driven aldosterone production. For other forms, mineralocorticoid receptor antagonists such as spironolactone or eplerenone are used to block the effects of excess aldosterone. In cases caused by a unilateral aldosterone-producing adenoma, surgical adrenalectomy may be curative. Early diagnosis and appropriate management are important to prevent long-term cardiovascular and renal complications associated with chronic aldosterone excess.

Common questions about Rare primary hyperaldosteronism